Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the Answer of 7 July 2026 to Question 13788 on Migraines: Drugs, whether NHS England's processes for reviewing and identifying themes from Prevention of Future Deaths reports have identified (a) propranolol toxicity and (b) psychiatric adverse drug reactions associated with migraine preventive medicines as a theme.

Individuals or organisations receiving a coroner’s Prevention of Future Deaths (PFD) report have a statutory obligation to respond to the report and a deadline of 56 days to do so.

NHS England has processes in place to review and consider learning from PFD reports relevant to National Health Services. PFD reports may be considered alongside information from a range of sources, including patient safety incident data, clinical evidence, coroner recommendations, and medicines safety information from the Medicines and Healthcare products Regulatory Agency (MHRA).

Where PFD reports identify concerns relating to medicines, including potential toxicity or psychiatric adverse effects associated with preventive migraine treatments, these issues can inform patient safety activity and service improvement work as appropriate. The MHRA is responsible for monitoring the safety of medicines in the United Kingdom through the Yellow Card scheme and other pharmacovigilance processes, and works with partners across the health system to identify and assess emerging safety signals. NHS England and healthcare providers are expected to have regard to relevant safety advice issued by the MHRA.